pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunization 145

Outsourcing Pharma

MARCH 3, 2021

The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic.

Vaccines 136

Vaccines 136

pharmaphorum

MARCH 16, 2021

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers.

Vaccines 138

Vaccines Documentation 138

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. over the last five years. A broad front.

Vaccines 134

Vaccines Immunization Compounding Pharmaceutical Companies 134

STAT

MARCH 4, 2024

Having Covid-19 increases a person’s risk of developing an autoimmune disease in the year after infection, a large study out of South Korea and Japan reports, but vaccination helps decrease that risk. Read the rest…

Vaccines 145

Vaccines Medical Records 145

Pharmaceutical Technology

JANUARY 29, 2024

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Vaccines 111

Vaccines 111

European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

MAY 9, 2024

Withdrawal of the marketing authorisation for the COVID-19 vaccine (ChAdOx1-S [recombinant]) Vaxzevria (SRD) by the European Medicines Agency on 7 May, follows a request by AstraZeneca. Global demand for all COVID vaccines is now much lower and overall supply exceeds demand.

Vaccines 110

Vaccines 110

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. The mRNA jab, developed by Pfizer and BioNTech, launched to huge fanfare in December 2020 and promised the start of the end of the coronavirus pandemic.

Vaccines 137

Vaccines Communication 137

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. Step forward on vaccines. The post AstraZeneca to supply nine million more vaccines to EU appeared first on.

Vaccines 115

Vaccines 115

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. In June 2022, Pfizer acquired 8.1%

Vaccines 119

Vaccines 119

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. Good news for everyone the Oxford vaccine trials are back up and running. We will back our scientists to deliver an effective vaccine as soon as safely possible [link].

Vaccines 104

Vaccines Immunization 104

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. The vaccine demonstrated a strong immune response in the trial.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . The novel vaccine, which is based on mosaic?8 How the novel coronavirus vaccine works. The novel vaccine?is

Vaccines 98

Vaccines Immunization 98

pharmaphorum

DECEMBER 10, 2020

The US government’s coronavirus vaccine chief has said that Pfizer/BioNTech’s vaccine could carry a warning that it should be avoided by people who are prone to serious allergic reactions. Both recovered after appropriate treatment. Both are recovering well.”.

Vaccines 103

Vaccines Documentation FDA 103

pharmaphorum

DECEMBER 30, 2020

The UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the fight against the pandemic, with first doses due to be administered on Monday. The #coronavirus vaccine is our way out of the pandemic – now we need to hold our nerve while we get through this together.

Vaccines 98

Vaccines Hospitals 98

pharmaphorum

DECEMBER 7, 2020

Tuesday has been dubbed “V-day” in the UK, when the first doses of Pfizer/BioNTech’s coronavirus vaccine will be distributed to the public outside of a clinical trial. Health secretary Matt Hancock reportedly came up with the wartime analogy to describe what will be the largest scale vaccination programme in the country’s history.

Vaccines 100

Vaccines 100

pharmaphorum

NOVEMBER 20, 2020

Pfizer and BioNTech have filed for emergency use of their COVID-19 vaccine candidate in the US, paving the way for a launch before year-end. On the efficacy side, the filing will highlight a vaccine efficacy rate of 95% in a phase 3 study testing patients with and without previous infection with SARS-CoV-2.

Vaccines 96

Vaccines Documentation FDA 96

pharmaphorum

OCTOBER 9, 2020

The European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 If the vaccines are approved and the contracts are fulfilled, they would supply more than two shots apiece for each of the EU’s 446 million inhabitants. — Johnson & Johnson (@JNJNews) October 8, 2020.

Vaccines 105

Vaccines 105

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.

Vaccines 105

Vaccines 105

STAT

OCTOBER 14, 2022

That’s how authorities were able to determine that the initial vaccines for Covid-19 were safe and effective on a large scale in 2020. Later, in 2021, when data showed that significant numbers of vaccinated people were becoming infected, health experts quickly instituted guidance for additional booster shots.

Vaccines 93

Vaccines 93

pharmaphorum

NOVEMBER 29, 2021

The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. It was billed at the time as a key tool to accelerate the development of new and innovative vaccines to combat some of the world’s most prevalent diseases, from discovery to licensed product.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Documentation Compounding FDA 108

pharmaphorum

DECEMBER 5, 2022

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccines 98

Vaccines FDA 98

pharmaphorum

JANUARY 7, 2021

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped. It gave CureVac €75 million in funding to develop CVnCoV last July, adding to around €100 million provided by the German government in 2020.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

OCTOBER 3, 2023

Sanofi and Janssen Pharmaceuticals have agreed to jointly develop and commercialise ExPEC9V, a 9-valent vaccine candidate for extraintestinal pathogenic E. Developed by Janssen, the potential first-in-class vaccine is currently in Phase III trials. coli vaccine (ExPEC9V) compared to placebo in the prevention of invasive E.

Vaccines 98

Vaccines 98

pharmaphorum

OCTOBER 1, 2020

The EU regulator is poised to start a review of AstraZeneca and Oxford University’s COVID-19 vaccine, but the FDA is widening its investigation into the shot’s safety, according to reports citing people close to the project. The post EMA review of AZ’s COVID-19 vaccine imminent; report appeared first on.

Vaccines 93

Vaccines FDA 93

pharmaphorum

MAY 6, 2021

Shares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents on them, a moved aimed to boost global supplies of the life-saving shots. Stocks hit by the news included companies such as Pfizer and Moderna, who are making profits from their COVID-19 vaccines.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Vaccines 98

Vaccines Immunization Process Improvement Compounding 98

pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. million in National Institutes of Health (NIH) funding to further develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccines 95

Vaccines Immunization Compounding 95

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

SEPTEMBER 16, 2020

In May, Germany pledged to provide up to €750 million ($889 million) in funding to support vaccines against COVID-19, and the main recipients have now been revealed – BioNTech, CureVac and IDT Biologika – which are all German biotechs. Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively.

Vaccines 86

Vaccines 86

pharmaphorum

DECEMBER 16, 2022

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. The world was caught unprepared for the global pandemic that struck in 2020. Vaccine access for a price. There are now efforts to ensure that the same is not allowed to happen again.

Vaccines 96

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 96

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccines 85

Vaccines Immunization 85